Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety

Alimentary Pharmacology and Therapeutics · Published 2026-06-29 · DOI 10.1111/apt.70830

Free full text

Authors (2)

Yousef Hakimi, Edward Giles

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Hakimi, Y., Giles, E. (2026). Letter: Low FODMAP Therapy in Paediatric Irritable Bowel Syndrome: Balancing Efficacy, Expectancy and Safety. Alimentary Pharmacology and Therapeutics. https://doi.org/10.1111/apt.70830

Related articles

• Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Letter: External Validation of Hepcidin Thresholds for Predicting Response to Iron Therapy in Active Inflammatory Bowel Disease · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Development and Validation of a Machine Learning Model to Prognosticate Hepatocellular Carcinoma · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Natural History of Recurrent Acute Pancreatitis: Implications for Interventional Trial Design · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Eosinophilic Oesophagitis Beyond the Oesophagus: High Prevalence of Chronic Rhinosinusitis‐Type Symptoms and Their Impact on Symptom Severity in Swiss EoE Cohort Study Patients · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Non‐Selective Beta‐Blocker Use Is Associated With Lower Mortality After Decompensation in Cirrhosis: A Nationwide Target Trial Emulation · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction‐Associated Steatohepatitis—Reanalysis of Fibrosis Stage 2–3 Subset · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• Clinical Outcomes After Percutaneous Coronary Intervention in Patients With Cirrhosis: A Multicentre National Study · Alimentary Pharmacology and Therapeutics · 2026 · Same journal
• A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection · Alimentary Pharmacology and Therapeutics · 2026 · Same journal